UNSPSC 51180000: Hormones and hormone antagonists

This classification denotes drugs that have a specific regulatory effect on the activity of a certain organ or organs.

UNSPSC 51180000 Hormones and hormone antagonists is a Family code with minimal recent state and local procurement activity directly aligned to its scope. The recent opportunities tagged to this code include a county purchasing department relocation notice, a reverse trade show event, vendor forums, and a pharmacy network RFQ—none of which involve the procurement of hormone medications or hormone antagonist pharmaceuticals. A Seminole County, Florida IFB does solicit naloxone (an opioid antagonist) and drug deactivation systems, and the City of Tucson Fire Department RFP includes basic and advanced life support pharmaceuticals and supplies distributed through vending machines, but these represent emergency-use antagonists and acute-care drugs rather than the hormone therapies the code nominally covers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP does establish multiple contracts for generic multi-source pharmaceuticals and OTC products with supply through authorized wholesalers, with proposals due March 26, 2026, but the scope emphasizes generic fill-rate management and administrative fee compliance rather than hormone-specific products.

The geographic and issuing-body mix shows activity concentrated in Florida (Seminole County, Pinellas County, Collier County) and Arizona (City of Tucson), with supporting cooperative purchasing through MMCAP serving state and local facilities across Minnesota and Oregon. The mismatch between the code's nominal scope and the actual recent opportunities suggests either mis-tagging by issuing bodies or that state and local procurement of hormone medications and antagonists falls under different UNSPSC classifications. Business development professionals should verify the specific pharmaceutical product categories their target accounts procure before pursuing opportunities tagged to this code.